explore -WSS

explore

author：leisure time 2025-09-28 08:32:51 - browse：46

Miniature people figurines standing in a group looking down. -- health tech coverage from STAT — Adobe

In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Christmas in the PICU brings some surprising joy

WSS

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Keeping primary care docs in field isn't impossible, says AAFP CEO

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Carvykti CAR

Why health records don't always know when patients are dead

Can sheer will power keep patients alive in their dying hours?

leisure time

explore

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

In Spain, a hospital brews its own CAR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cigna wins case to block Amy Bricker's move to CVS

BioMarin wins approval for gene therapy to treat hemophilia A

David Ricks of Eli Lilly: best biopharma CEO of 2023

Virginia high school admissions case could be legal follow

Cheap, fast test for Zika and dengue could cost just $1

Medical leaders decry Supreme Court decision on affirmative action

David Ricks of Eli Lilly: best biopharma CEO of 2023

explore

The system is set up to fail children with medical complexity

5 takeaways from STAT's examination of Zynex Medical

Medical device trials still don't enroll enough women, study finds

Virtual care provider acquires bankrupt Pear's prescription apps

Hospitals owned by private equity see complications spike 25%

Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

leisure time

focus

explore